LEADER 03940nam  2201033z- 450 
001 9910595076103321
005 20231214133349.0
035   $a(CKB)5680000000080765
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/92063
035   $a(EXLCZ)995680000000080765
100   $a20202209d2022      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aNovel Biomarkers of Gastrointestinal Cancer
210   $aBasel$cMDPI Books$d2022
215   $a1 electronic resource (248 p.)
311   $a3-0365-4932-3 
311   $a3-0365-4931-5 
330   $aGastrointestinal (GI) cancer is a major cause of morbidity and mortality in the world. Since early diagnosis and optimal treatment selection are crucial to improving the prognosis of these diseases, the discovery of useful biomarkers has the potential to greatly reduce their burden. Recent technical and mechanical developments have allowed for the detection of tiny differences in various factors modified in physical conditions, which could contribute to the discovery of novel biomarkers for some diseases.In this Special Issue, we aim to focus on novel biomarkers for GI cancers, including esophageal cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer and biliary cancer. In addition, any samples (tissue, blood, urine and feces) are useful as biomarker sources, although body-fluid-based biomarkers are promising as diagnostic biomarkers due to their noninvasiveness. This Special Issue aims to collect novel insights clarifying the current situation and future perspective in this field.
606   $aMedicine$2bicssc
606   $aOncology$2bicssc
610   $acolorectal cancer
610   $aadvanced adenoma
610   $ascreening
610   $astool
610   $amRNA
610   $acancer screening
610   $acirrhosis
610   $aAFP
610   $amachine learning
610   $aMALDI-TOF
610   $aproteomics
610   $aCXCR4
610   $aprognosis
610   $aoverall survival
610   $arectal cancer
610   $aneoadjuvant chemoradiation
610   $amouse model
610   $abiomarkers
610   $aurokinase plasminogen activator (uPA)
610   $aurokinase plasminogen activator receptor (uPAR)
610   $aplasminogen activator inhibitor type 1 (PAI-1)
610   $acirculating tumour cell (CTC)
610   $agastric cancer
610   $aoesophageal cancer
610   $aserine proteases
610   $atumour microenvironment
610   $aserpins
610   $abiomarker
610   $achemoresistance
610   $aliquid biopsy
610   $amicroRNA
610   $along non-coding RNA
610   $acolorectal neoplasms
610   $acancer screening tests
610   $aearly detection of cancer
610   $aprecision medicine
610   $aunfolded protein
610   $ahepatocellular cancer
610   $aGSVA
610   $aunfolded protein score
610   $aepigenetic regulation genes
610   $asomatic mutations
610   $amolecular genetic markers
610   $aextracellular vesicles
610   $amicrobiome
610   $a16S rRNA amplicon
610   $ametagenomics
610   $aliver fibrosis
610   $ahepatocellular carcinoma
610   $arecurrence
610   $aSHG/TPEF microscopy
610   $aartificial intelligence
610   $aadvanced gastric cancer
610   $atargeted therapy
610   $aurinary miRNA
610   $amiR-129-1-3p
610   $amiR-566
615  7$aMedicine
615  7$aOncology
700   $aShimura$b Takaya$4edt$01329046
702   $aShimura$b Takaya$4oth
906   $aBOOK
912   $a9910595076103321
996   $aNovel Biomarkers of Gastrointestinal Cancer$93039266
997   $aUNINA